Cell-based therapies: Careful safety assessment for minimization of risk

Research output: Contribution to journalArticlepeer-review

Abstract

Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.

Original languageEnglish
Pages (from-to)710-712
Number of pages3
JournalCytotherapy
Volume12
Issue number6
DOIs
Publication statusPublished - Oct 2010

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Cell-based therapies: Careful safety assessment for minimization of risk'. Together they form a unique fingerprint.

Cite this